Abstract
Essential hypertension is a heritable disease with a complex genetic trait caused by multiple susceptibility genes the effects of which are modulated by gene–environment and gene–gene interactions [1]. These genetic determinants involve multiple genes that make it challenging to study blood pressure BP) variations in general population [2]. BP may be dependent on a genetic pattern of many loci with influence at variance according to race [3], gender [4], age, or lifestyle [5].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Singh M, Singh AK, Pandey S, Chandra S, Singh KA, Gambhir IS. Molecular genetics of essential hypertension. Clin Exp Hypertens. 2016;38(3):268–77.
Doris PA. Hypertension genetics, single nucleotide polymorphisms, and the common disease: common variant hypothesis. Hypertension. 2002;39:323–31.
Luft FC, Miller JZ, Grim CE, Fineberg NS, Christian JC, Daugherty SA, et al. Salt sensitivity and resistance of blood pressure. Age and race as factors in physiological responses. Hypertension. 1991;17:1102–8.
Higaki J, Baba S, Katsuya T, Sato N, Ishikawa K, Mannami T, et al. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita Study. Circulation. 2000;101:2060–5.
Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet. 2003;361:1629–41.
Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545–56.
Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119–23.
Inoue I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest. 1997;99:1786–97.
O’Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation. 1998;97:1766–72.
Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension. 1998;32:198–204.
Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262–5.
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–6.
Haximer SP, Watson N, Linder ME, Blumer KJ, Hepler JR. RGS2/G0S8 is a selective inhibitor of Gqalpha function. Proc Natl Acad Sci U S A. 1997;94:14389–93.
Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rheee M, Peng N, et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deeficient mice. J Clin Invest. 2003;111:445–52.
Lander E, Kruglyak L. Genetic dissection of complex traits. Nat Genet. 1995;11:241–7.
Patel RS, Masi S, Taddei S. Understanding the role of genetics in hypertension. Euro Heart J. 2017;38:2309–12.
Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J. 2013;34:951–61.
Dominiczak A, Delles C, Padmanabhan S. Genomics and precision medicine for clinicians and scientists in hypertension. Hypertension. 2017;69:e10–3.
Wang J, Gong L, Tan Y, Hui R, Wang Y. Hypertensive epigenetics: from DNA methylation to microRNAs. J Hum Hypertens. 2015;29:575–82.
Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412–25.
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.
Wain LV, Vaez A, Jansen R, Joehanes R, van der Most PJ, Mesut Erzurumluoglu A, et al. Novel blood pressure locus and gene discovery using genome-wide association study and expression data sets from blood and the kidney. Hypertension. 2017;70:e4–e19.
Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103–9.
Evangelou E, Warren H R, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over one million people identifies 535 new loci associated with blood pressure traits. Nat. Genet. 2018;50:1412–25.
Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371(9628):1921–6.
Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173:10–20.
Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat Genet. 2017;49:403–15.
Oliveira-Paula GH. Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol. 2015;71:949–57.
Ciolac EG, Bocchi EA, Bortolotto LA, Carvalho VO, Greve JMD, Guimaraes GV. Haemodynamic, metabolic and neuro-humoral abnormalities in young normotensive women at high familial risk for hypertension. J Hum Hypertens. 2010;24:814–22.
Bond V Jr, Franks BD, Tearney RJ, Wood B, Melendez MA, Johnson L, et al. Exercise blood pressure response and skeletal muscle vasodilator capacity in normotensives with positive and negative family history of hypertension. J Hypertens. 1994;12:285–90.
Esler M. The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol. 2010;108(2):227–37.
Fisher JP, Paton JFR. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J Hum Hypertens. 2012;26:463–75.
Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens. 2004;17:217–22.
Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension: review of 122 cases. Lancet. 1953;1:403–8.
Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens. 2007;9:399–405.
Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114:1804–14.
Grassi G, Seravalle G, Bertinieri G, Turri C, Dell’Oro R, Stella M, et al. Sympathetic and reflex alterations in systo-diastolic and systolic hypertension of the elderly. J Hypertens. 2000;18:587–93.
Thorp AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res. 2015;2015:341583.
Grassi G, Cattaneo BM, Lanfranchi SG, Mancia G. Baroflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68–72.
Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell-Oro R, Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846–51.
Kaur J, Young BE, Fadel PJ. Sympathetic overactivity in chronic kidney disease: consequences and mechanisms. Int J Mol Sci. 2017;18:1682–94.
Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens. 2010;23:1052–60.
Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63:451–8.
Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens. 2013;10:2018–24.
Mercado-Asis LB, Castillo RR. Clinical presentation, diagnosis, and management of primary aldosteronism and pheochromocytoma. Hypertens J. 2019;5:5.
Mercado-Asis LB, Siao RM, Amba NF. Evolving clinical presentation and assessment of pheochromocytoma: a review. J Med Univ Santo Tomas. 2017;1:5–23.
Eisenhofer G, Lenders JW, Timmers HJLM, Mannelli M, Grebe SK, Hofbauer LC, et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem. 2011;57:411–20.
Pacak K. Pheochromocytoma: a catecholamine and oxidative stress disorder. Endocr Regul. 2011;45:65–90.
van Berkel A, Lenders J, Timmers HJLM. Biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol. 2014;170:R109–19.
Pussard E, Chaouch A, Said T. Radioimmunoassay of free plasma metanephrines for the diagnosis of catecholamine producing tumors. Clin Chem Lab Med. 2014;52:437–44.
Osinga TE, van den Eijnden HA, Kema IP, Kerstens MN, Dullaart RPF, de Jong WHA, et al. Unilateral and bilateral adrenalectomy for pheochromocytoma requires adjustment of urinary and plasma meetanephrine reference ranges. J Clin Eendocrinol Metab. 2013;98:1976–083.
Zhou GW, Wei Y, Chen X, Jiang XH, Li XY, Ning G, et al. Diagnosis and surgical treatment of multiple endocrine neoplasia. Chin Med J. 2009;122:1495–500.
Mercado-Asis LB, Tingcungco AG, Bolong DT, Lopez RA, Caguioa EV, Yamamoto ME, et al. Diagnosis of small adrenal pheochromocytoma by adrenal venous sampling with glucagon stimulation test. Int J Endocrinol Metab. 2011;9:323–9.
Malong CLP, Tanchee-Ngo MJ, Torres-Salvador P, Pacak K, Mercado-Asis LB. Removal of dominant adrenal lateralized by glucagon-stimulated adrenal venous sampling alleviates hypertension in bilateral pheochromocytoma. J Life Sci. 2013;7:586–91.
Gomez MF, Gan FR, Mendoza E, Mercado LB. Systemic hormonal unloading in unilateral adrenalectomy in a patient with bilateral adrenal hyperplasia: a case report. J Med Univ Santo Tomas. 2019;3:303–8.
Oparil S. The sympathetic nervous system in clinical and experimental hypertension. Kidney Int. 1986;30:437–52.
Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. J Hypertens Suppl. 1996;14:S159–65.
Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34:724–8.
Esler M. Sympathetic nervous system moves toward center stage in cardiovascular medicine: from Thomas Willis to resistant hypertension. Hypertension. 2014;63:e25–32.
Sinski M, Lewandowski J, Przybylski J, Zalewski P, Symonides B, Abramczyk P, et al. Deactivation of carotid body chemoreceptors by hyperoxia decreases blood pressure in hypertensive patients. Hypertens Res. 2014;37:858–62.
Cowleey AW Jr. Long-teerm control of arterial blood pressure. Physiol Rev. 1992;72:231–300.
Sinski M, Lewandowski J, Przybylski J, Bidiuk J, Abramczyk P, Ciarka A, Gaciong Z. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens Res. 2012;35:487–91.
Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hyperrtension. 2009;54:690–7.
Bang SK, Ryu Y, Chang S, Im CK, Bae JH, Gwak YS, et al. Attenuation of hypertension by C-fiber stimulation of the human median nerve and the concept-based novel device. Sci Rep. 2018;8:14967.
de Jong MR, Adiyaman A, Gal P, Smit JJJ, Delnoy PPHM, Heeg J, van Hasselt BAAM, et al. Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation. Hypertension. 2016;68:707–14.
Maver J, Struci M, Accetto R. Autonomic nervous system in normotensive subjects with a family history of hypertension. Clin Auton Res. 2004;14:369–75.
Elayan HH, Sun P, Milic M, Liu F, Bao X, Ziegler MG. Cardiovascular responses to electrical stimulation of sympathetic nerves in the pithed mouse. Auton Neurosci. 2008;30:49–52.
Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res. 2017;125:21–38.
Munoz-Durango N, Fuentes CA, Castillo AE, Gonzalees-Gomeez LM, Veecchiola A, Fardella CE, Kaleergis AM. Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension. Int J Mol. 2016;17:797–814.
Ren L, Lu X, Danser AHJ. Revisiting the brain renin-angiotensin system—focus on novel therapies. Curr Hypertens Rep. 2019;21:28–35.
Nehme A, Zouein FA, Zayeri ZD, Zibara K. An update on the tissue renin angiotensin system and its role in physiology and pathology. J Cardiovasc Dev Dis. 2019;6:14–31.
Sztechman D, Czarzasta K, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Zera T. Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries. J Physiol Pharmacol. 2018;69.
Santos RAS, Oudit GY, Verano-Braga T, Canta G, Steckelings UM, Bader M. The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol. 2019;316:H958–70.
Reen L, Lu X, Danser AHJ. Revisiting the brain renin-angiotensin system—focus on novel therapies. Curr Hypertens Rep. 2019;21:28–35.
Hamlyn JM, Linde CI, Gao J, Huang BS, Golovina VA, Balustein MP, et al. Neuroendocrine humoral and vascular components in the pressor pathway for brain angiotensin II: a new axis in long term blood pressure control. PLoS One. 2014;9:e108916.
Lu J, Wang H, Ahmad M, Keshtkar-Jahromi M, Blaustein MP, Hamlyn JM, Leeneen FHH. Central and peripheral slow-pressor mechanisms contributing to angiotensin II-salt hypertension in rats. Cardiovasc Res. 2018;114:233–46.
Leenen FH. The central role of the brain aldosterone “ouabain” pathway in salt-sensitive hypertension. Biochem Biophys Acta. 2010;1802:1132–9.
Huang BS, Ahmadi M, White RA, Leenen FH. Central neuronal activation and pressor responses induced by circulating ANG II: role of the brain aldosterone “ouabain” pathway. Am J Physiol Heart Circ Physiol. 2010;299:H422–30.
Osborn JW, Olson DM, Guzman P, Toney GM, Fink GD. The neurogenic phase of angiotensin II-salt hypertension is prevented by chronic intracerebroventricular administration of benzamil. Physiol Rep. 2014;2:e00245.
Wang Y, Chen L, Wier WG, Zhang J. Intravital Forster resonance energy transfer imaging reveals elevated [Ca2+], and enhanced sympathetic tone in femoral arteries of angiotensin II-infused hypertensive biosensor mice. J Physiol. 2013;591:5321–36.
Gonzales-Villalobos RA, Billet S, Kim C, Satou R, Fuchs S, Berrnstein KE, et al. Intrarenal angiotensin-converting enzyme induces hypertension in response to angiotensin I infusion. J A Soc Nephrol. 2011;22:449–59.
Bernstein KEE. Two ACEs and a heart. Nature. 2002;417:799–802.
Wilson WL, Roques BP, Llorens-Cortes C, Speth RC, Harding JW, Wright JW. Roles of brain angiotensins II and III in thirst and sodium appetite. Brain Res. 2005;1060:108–17.
Bodineau L, Frugiere A, Marc Y, Inguimbert N, Fassot C, Balavoine F, Roques B, Llorens-Cortes C. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension. 2008;51:1318–25.
Raina H, Zhang Q, Rhee AY, Pallone TL, Wier WG. Sympathetic nerves and the endothelium influence the vasoconstrictor effect of low concentrations of ouabain in pressurized small arteries. Am J Physiol Heart Circ Physiol. 2010;298:H2093–101.
Hamlyn JM, Laredo J, Shah JR, Lu ZR, Hamilton BP. 11-hydroxylation in the biosynthesis of endogenous ouabain: multiple implications. Ann N Y Acad Sci. 2003;986:685–93.
Mellon SH, Griffin LD, Compagnone NA. Biosynthesis and action of neurosteroids. Brain Res Rev. 2001;37:3–12.
Asano N, Ogura T, Mimura Y, Kishida M, Kataoka H, Otsuka F, et al. Renal AT1 receptor: autographic localization and quantification in rat. Res Commun Mol Pathol Pharmacol. 1998;100(2):161–70.
Vinson GP. Glomerulosa function and aldosterone synthesis in the rat. Mol Cell Endocrinol. 2004;217:59–65.
Wysocki J, Ye M, Batlle D. Plasma and kidney angiotensin peptides: importance of the aminopeptidase A/angiotensin III axis. Am J Hypertens. 2015;28:1418–28.
Ye P, Kenyon CJ, MacKenzie SM, Seckl JR, Fraser R, et al. Regulation of aldosterone synthase gene expression in the rat adrenal gland and central nervous system by sodium and angiotensin II. Endocrinology. 2003;144:3321–8.
Carey RM, Vaughan ED Jr, Peach MJ, Ayers CR. Activity of (des-Aspartyl1)-angiotensin II and angiotensin II in man. Differences in blood pressure and adrenocortical response during normal and low sodium intake. J Clin Invest. 1978;61:20–31.
Kemp BA, Bell JF, Rottkamp DM, Howell NL, Shao W, Navar LG, et al. Intrarenal angiotensin III is the predominant agonist for proximal tubule AT2 receptors. Hypertension. 2012;60:387–95.
Padia SH, Howell NL, Siragy HM, Carey RM. Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension. 2006;47:537–44.
Kopf PG, Park S, Herrnreiter A, Krause C, Roques BP, Campbell WB. Obligatory metabolism of angiotensin II to angiotensin III for zona glomerulosa cell-mediated relaxations of bovine adrenal cortical arteries. Endocrinology. 2018;159:238–47.
de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology, XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415–72.
Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev. 2018;98(3):1627–738.
Carey RM. Update on angiotensin AT2 receptors. Curr Opin Nephrol Hypertens. 2017;26:91–6.
Siragy HM, Carey RM. Angiotensin type 2 receptors: potential importance in the regulation of blood pressure. Curr Opin Nephrol Hypertens. 2001;10:99–103.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):e127–248.
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burner M, Clement DL, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.
Grebla RC, Rodriguez CJ, Borrell LN, Pickering TG. Prevalence and determinants of isolated systolic hypertension among young adults: the 1999–2004 US National Health and Nutrition Examination Survey. J Hypertens. 2010;28(1):15–23.
Yano Y, Stamler J, Garside DB, Daviglus ML, Franklin SS, Carnethon MR, et al. Isolated systolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry Study. J Am Coll Cardiol. 2015;65(4):327–35.
McEniery CM, Franklin SS, Cockcroft JR, Wilkinson IB. Isolated systolic hypertension in young people is not spurious and should be treated: pro side of the argument. Hypertension. 2016;68(2):269–75.
Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25(3):305–13.
Franklin SS. Elderly hypertensives: how are they different? J Clin Hypertens. 2012;14(11):779–86.
Palatini P, Rosei EA, Avolio A, Bilo G, Casiglia E, Ghiadoni L, et al. Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension. J Hypertens. 2018;36(6):1222–36.
Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235–481.
Avolio AP, Deng FQ, Li WQ, Luo YF, Huang ZD, Xing LF, et al. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation. 1985;71(2):202–10.
Avolio A. Ageing and wave reflection. J Hypertens Suppl. 1992;10(6):S83–6.
Mitchell GF, Lacourciere Y, Ouellet JP, Izzo JL, Neutel J, Kwerwin LJ, et al. Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationship. Circulation. 2003;108(13):1592–8.
Wallace SM, Yasmin, McEniery CM, Maki-Petaja KM, Booth AD, Cockcroft JR, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension. 2007;50(1):228–33.
Franklin SS, Barboza MG, Pio JR, Wong ND. Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. J Hypertens. 2006;24(10):2009–16.
Mph CB, Goel S, Messerli FH, Bavishi C, Goel S, Messerli FH. Isolated systolic hypertension: an update after SPRINT. Am J Med. 2010;129(12):1251–8.
Kocemba J, Kawecka-Jaszcz K, Gryglewska B, Grodzicki T. Isolated systolic hypertension: pathophysiology, consequences and therapeutic benefits. J Hum Hypertens. 1998;12:621–6.
Kario K, Chen CH, Park S, Park CG, Hoshide S, Cheng HM, et al. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics. Hypertension. 2018;71(3):375–82.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Mercado-Asis, L.B. (2022). Pathophysiology and Mechanisms of Hypertension (Asian Context). In: Ram, C.V.S., Teo, B.W.J., Wander, G.S. (eds) Hypertension and Cardiovascular Disease in Asia. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-030-95734-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-95734-6_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-95733-9
Online ISBN: 978-3-030-95734-6
eBook Packages: MedicineMedicine (R0)